Drug Profile
GC 2107
Alternative Names: CB02-0133; FXa inhibitor - LegoChem Biosciences; GC-2107; GC4401; GCC-2107; GCC-4401; GCC-4401C; I Fxa - LegoChem Biosciences; LCB-02-0133; NokxabanLatest Information Update: 01 Apr 2022
Price :
$50
*
At a glance
- Originator LegoChem Biosciences
- Developer GC Pharma; LegoChem Biosciences
- Class Anticoagulants; Antithrombotics; Small molecules
- Mechanism of Action Factor Xa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Embolism; Stroke; Venous thromboembolism
Most Recent Events
- 29 Mar 2022 GC Pharma is now called GC Biopharma
- 05 Apr 2021 No development reported - Phase-II for Embolism (Prevention) in USA (PO)
- 05 Apr 2021 No development reported - Phase-II for Stroke (Prevention) in USA (PO)